Quest Diagnostics Inc
NYSE:DGX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
150.33
192.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
DGX
stock under the Base Case scenario is
190.48
USD.
Compared to the current market price of 184.18 USD,
Quest Diagnostics Inc
is
Undervalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Quest Diagnostics Inc.
| US |
|
CVS Health Corp
NYSE:CVS
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
|
| US |
|
Cigna Corp
NYSE:CI
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Quest Diagnostics faces mounting pressure on reimbursement rates from government programs and commercial insurers, which could significantly compress margins and limit revenue growth over the long term.
Increasing competition from independent labs, hospital-based labs, and growing direct-to-consumer testing services threatens Quest Diagnostics’ market share, particularly as smaller, more specialized competitors continue to emerge.
The post-pandemic decline in COVID-19 testing volumes exposes Quest Diagnostics to unpredictable swings in overall testing demand, while its sizable compliance and regulatory costs may hamper operational flexibility in periods of reduced test volumes.
Quest Diagnostics’ extensive national lab network and established payer relationships position it to leverage scale and offer competitively priced testing, helping defend market share and solidify top-line growth.
The company’s strategic shift toward higher-margin advanced diagnostic services, including genetic and molecular testing, could boost profitability and drive incremental revenue over the long term.
Quest Diagnostics’ strong balance sheet and track record of targeted acquisitions support ongoing expansion into specialized testing niches and new healthcare partnerships, reinforcing its leadership in the diagnostic space.
Revenue & Expenses Breakdown
Quest Diagnostics Inc
Balance Sheet Decomposition
Quest Diagnostics Inc
| Current Assets | 2.4B |
| Cash & Short-Term Investments | 432m |
| Receivables | 1.5B |
| Other Current Assets | 519m |
| Non-Current Assets | 13.8B |
| Long-Term Investments | 137m |
| PP&E | 2.8B |
| Intangibles | 10.6B |
| Other Non-Current Assets | 296m |
| Current Liabilities | 2.1B |
| Accounts Payable | 1.5B |
| Accrued Liabilities | 173m |
| Other Current Liabilities | 504m |
| Non-Current Liabilities | 6.8B |
| Long-Term Debt | 5.2B |
| Other Non-Current Liabilities | 1.6B |
Free Cash Flow Analysis
Quest Diagnostics Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Quest Diagnostics Inc
|
Revenue
|
10.9B
USD
|
|
Cost of Revenue
|
-7.2B
USD
|
|
Gross Profit
|
3.6B
USD
|
|
Operating Expenses
|
-2B
USD
|
|
Operating Income
|
1.6B
USD
|
|
Other Expenses
|
-633m
USD
|
|
Net Income
|
963m
USD
|
DGX Profitability Score
Profitability Due Diligence
Quest Diagnostics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Quest Diagnostics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
DGX Solvency Score
Solvency Due Diligence
Quest Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Quest Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DGX Price Targets Summary
Quest Diagnostics Inc
According to Wall Street analysts, the average 1-year price target for
DGX
is 200.59 USD
with a low forecast of 170.87 USD and a high forecast of 225.75 USD.
Dividends
Current shareholder yield for
DGX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
DGX
stock under the Base Case scenario is
190.48
USD.
Compared to the current market price of 184.18 USD,
Quest Diagnostics Inc
is
Undervalued by 3%.